Progranulin: A growth factor, a novel TNFR ligand and a drug target
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Progranulin (PGRN) is abundantly expressed in epithelial cells, immune cells, neurons, and chondrocytes, and reportedly contributes to tumorigenesis. PGRN is a crucial mediator of wound healing and tissue repair. PGRN also functions as a neurotrophic factor and mutations in the PGRN gene resulting in partial loss of the PGRN protein cause frontotemporal dementia. PGRN has been found to be a novel chondrogenic growth factor and to play an important role in cartilage development and inflammatory arthritis. Although research has shown that PGRN exhibits anti-inflammatory properties, the details about the exact molecular pathway of such effects, and, in particular, the PGRN binding receptor, have not been identified so far. Recently, researchers have shown that PGRN binds to tumor necrosis factor (TNF)-receptors (TNFR), interfering with the interaction between TNFα and TNFR. They further demonstrated that mice deficient in PGRN are susceptible to collagen-induced arthritis, an experimental model of rheumatoid arthritis, and that administration of PGRN reversed the arthritic process. An engineered protein made of three PGRN fragments (Atsttrin), displayed selective TNFR binding and was more active than natural PGRN. Both PGRN and Atsttrin prevented inflammation in various arthritis mouse models and inhibited TNFα-induced intracellular signaling pathways. Thus, PGRN is a key regulator of inflammation and it may mediate its anti-inflammatory effects, at least in part, by blocking TNF binding to its receptors. As we discuss here, TNFR-based interventions may both stimulate and suppress the growth of cancer cells, and the same may be true in analogy for Atsttrin as a new player.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512 · cited 10×
“Studies now in progress will show which TNFR–PGRN interactions occur in frontocortical brain regions, but it is probable that future studies will identify more multi-ligand cell-surface receptors for PGRN, thereby supplying a better overall vision of PGRN cell-signaling pathways which are abrogated in FTLD-TDP (Kumar-…”
BackgroundInfluentialFDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · cited 1×
“Screening showed that suberoylanilide hydroxamic acid (SAHA), an FDA-approved histone deacetylase (HDAC) inhibitor currently used clinically to treat cutaneous T-cell lymphoma (Mann et al., 2007), enhances PGRN expression in various types of cells in cultures.”
BackgroundSortilin is essential for proNGF-induced neuronal cell death
Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T. E., et al. (2004) · Nature · doi:10.1038/nature02319 · Cited by 962 · cited 2×
“Sortilin is known to be a multi-ligand neural receptor that also interacts with other neural growth factors, including nerve growth factor (NGF) (Nykjaer et al., 2004) and brain-derived neurotrophic factor (BDNF) (Chen et al., 2005).”
BackgroundTang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., Syed, N. M., Lai, Y., Lin, E. A., Kong, L., et al. (2011) · Science · doi:10.1126/science.1199214 · Cited by 761
Self-citationProgranulin is a mediator of the wound response
He, Z., Ong, C. H. P., Halper, J., & Bateman, A. (2003) · Nature Medicine · doi:10.1038/nm816 · Cited by 490 · cited 2×
“High levels of PGRN expression have been reported in human cancers, and PGRN is strongly believed to contribute to tumorigenesis (Bateman et al., 1990; Zhang & Serrero, 1998; Gonzalez et al., 2003; He & Bateman, 2003; He et al., 2003; Jones et al., 2003; Wang et al., 2003; Davidson et al., 2004).”
BackgroundExaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice
Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T., Ma, X., Ma, Y., Iadecola, C., Beal, M. F., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091568 · Cited by 480 · cited 3×
“Progranulin in neuronal degeneration diseases PGRN is a neurotrophic factor (Van Damme et al., 2008; Yin et al., 2010b), with PGRN gene mutations that result in partial loss of the PGRN protein causing frontotemporal dementia, also known as frontotemporal lobar degeneration (FTLD) (Baker et al.,…”
BackgroundTNF receptor 2 pathway: drug target for autoimmune diseases
Faustman, D., & Davis, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3030 · Cited by 446 · cited 2×
“…terms of both biochemical (PGRN exhibits ~600- fold higher binding affinity to TNFR2 than TNFα) and functional evidences (PGRN and TNFR2 mediate beneficial and protective roles in the inflammatory processes) (Zhu et al., 2002; Kessenbrock et al., 2008; Bluml et al., 2010; Faustman & Davis, 2010).”
BackgroundYin, F., Dumont, M., Banerjee, R., Ma, Y., Li, H., Lin, M. T., Beal, M. F., Nathan, C., Thomas, B., & Ding, A. (2010) · The FASEB Journal · doi:10.1096/fj.10-161471 · Cited by 180 · cited 3×
“Progranulin in neuronal degeneration diseases PGRN is a neurotrophic factor (Van Damme et al., 2008; Yin et al., 2010b), with PGRN gene mutations that result in partial loss of the PGRN protein causing frontotemporal dementia, also known as frontotemporal lobar degeneration (FTLD) (Baker et al.,…”
Background
Cited by
The Role of Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of Osteoarthritis
Wojdasiewicz, P., Poniatowski, Ł. A., & Szukiewicz, D. (2014) · Mediators of Inflammation · doi:10.1155/2014/561459 · Cited by 1,608
Scaffolds for bone tissue engineering: state of the art and new perspectives
Roseti, L., Parisi, V., Petretta, M., Cavallo, C., Desando, G., Bartolotti, I., & Grigolo, B. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.05.017 · Cited by 1,320
A new immunometabolic perspective of intervertebral disc degeneration
Francisco, V., Pino, J., González-Gay, M. Á., Lago, F., Karppinen, J., Tervonen, O., Mobasheri, A., & Gualillo, O. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00713-z · Cited by 462
Fang, W., Zhou, T., Shi, H., Yao, M., Zhang, D., Qian, H., Zeng, Q., Wang, Y., Jin, F., Chai, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01786-6 · Cited by 256
Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
“In general, progranulin appears to maintain inflammation within physiologically appropriate limits, and in its absence, a wide range of non-neuronal conditions with an inflammatory component exhibit a more severe phenotype (Liu, 2011; Wu and Siegel, 2011; Liu and Bosch, 2012; Miller et al., 2013).”
BackgroundBi, J., Zhang, L., Zhang, P., Xu, S., Liu, Y., Zhang, X., Qiu, X., Bi, Y., Yan, F., Wei, H., et al. (2024) · Biomaterials Research · doi:10.34133/bmr.0075 · Cited by 12
Metadata
- Authors
- Liu, C.-J., & Bosch, X.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 133
- Issue
- 1
- Pages
- 124-132
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2050705743
- Cited by
- 133
- References
- 9
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.